2024 ICD-10-CM Diagnosis Code M33.00

Approximate Synonyms

The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:

• Calcinosis due to childhood type dermatomyositis
• Childhood type dermatomyositis
• Childhood type dermatomyositis
• Connective tissue disease overlap syndrome
• Dermatomyositis
• Juvenile dermatomyositis overlap syndrome
• Lipodystrophy due to juvenile dermatomyositis
• Overlap syndrome

Clinical Information

• Dermatomyositis

  a subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. the illness occurs with approximately equal frequency in children and adults. the skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. the disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. the childhood form of this disease tends to evolve into a systemic vasculitis. dermatomyositis may occur in association with malignant neoplasms. (from adams et al., principles of neurology, 6th ed, pp1405-6)

• Exosome Component 10|Autoantigen PM-SCL|Autoantigen PM/Scl|EC 3.1.13.-|EXOSC10|P100 Polymyositis-Scleroderma Overlap Syndrome-Associated Autoantigen|PM/Scl-100|Polymyositis/Scleroderma Autoantigen 100 kDa|Polymyositis/Scleroderma Autoantigen 2

  exosome component 10 (885 aa, ~101 kda) is encoded by the human exosc10 gene. this protein plays a role in the maturation and degradation of rna.

• Other Overlap Syndromes|Other overlap syndromes

  evidence of other overlap syndromes not specified elsewhere.

• Overlap Syndrome

  an autoimmune, connective tissue disorder in which the patient exhibits features from two or more diseases. these typically include systemic sclerosis, dermatomyositis, polymyositis, rheumatoid arthritis, systemic lupus erythematosus, and sjogren syndrome; in pediatrics the respective pediatric entities are encountered.

• Scleroderma Polymyositis Overlap Syndrome|Scleroderma Polymyositis

  a rare autoimmune disorder in which patients present with overlapping symptoms of systemic scleroderma and polymyositis or dermatomyositis.

• Adult Dermatomyositis

  dermatomyositis in an adult.

• Childhood Dermatomyositis|JDM|JDM|Juvenile Dermatomyositis|Juvenile Dermatomyositis

  an inflammatory myopathy of childhood resulting in muscle weakness, and associated with a characteristic skin rash.

• Cutaneous Dermatomyositis Disease Area and Severity Index|CDASI|CDASI

  an instrument that measures activity and damage in the skin of dermatomyositis patients.

• Dermatomyositis

  inflammation of the skin and muscle.

• Dermatomyositis Skin Severity Index|DSSI|DSSI

  an assessment of disease activity in the skin of patients with dermatomyositis.

• Interferon-Induced Helicase C Domain-Containing Protein 1|CADM-140 Autoantigen|Clinically Amyopathic Dermatomyositis Autoantigen 140 kDa|EC 3.6.4.13|Helicard|Helicase with 2 CARD Domains|IFIH1|Interferon-Induced With Helicase C Domain Protein 1|MDA-5|Melanoma Differentiation Associated Protein-5|Melanoma Differentiation-Associated Protein 5|Murabutide Down-Regulated Protein|RLR-2|RNA Helicase-DEAD Box Protein 116

  interferon-induced helicase c domain-containing protein 1 (1025 aa, ~117 kda) is encoded by the human ifih1 gene. this protein is involved in the positive regulation of antiviral responses.

• Juvenile Dermatomyositis Sine Myositis|Juvenile Amyopathic Dermatomyositis|Juvenile Amyopathic Dermatomyositis|Juvenile Dermatomyositis sine Myositis|Juvenile dermatomyositis without myopathy

  a rare form of juvenile dermatomyositis that manifests with characteristic cutaneous findings for at least six months in the absence of any detectable muscle involvement.

• Juvenile Dermatomyositis with Myopathy|Juvenile dermatomyositis with myopathy

  evidence of juvenile dermatomyositis with myopathy.

• Juvenile Dermatomyositis with Other Organ Involvement|Juvenile dermatomyositis with other organ involvement

  evidence of juvenile dermatomyositis with other organ involvement.

• Juvenile Dermatomyositis with Respiratory Involvement|Juvenile dermatomyositis with respiratory involvement

  evidence of juvenile dermatomyositis with respiratory involvement.

• Juvenile Dermatomyositis, Organ Involvement Unspecified|Juvenile dermatomyositis, organ involvement unspecified

  evidence of juvenile dermatomyositis, organ involvement unspecified.

• Other Dermatomyositis with Myopathy|Other dermatomyositis with myopathy

  evidence of other dermatomyositis with myopathy not specified elsewhere.

• Other Dermatomyositis with Other Organ Involvement|Other dermatomyositis with other organ involvement

  evidence of other dermatomyositis with other organ involvement not specified elsewhere.

• Other Dermatomyositis with Respiratory Involvement|Other dermatomyositis with respiratory involvement

  evidence of other dermatomyositis with respiratory involvement not specified elsewhere.

• Other Dermatomyositis without Myopathy|Other dermatomyositis without myopathy

  evidence of other dermatomyositis without myopathy not specified elsewhere.

• Other Dermatomyositis, Organ Involvement Unspecified|Other dermatomyositis, organ involvement unspecified

  evidence of other dermatomyositis, organ involvement unspecified not specified elsewhere.

M33.00 is grouped with Diagnostic Related Groups - MS-DRG Mapping

Diagnostic Related Groups (DRGs) are a classification system used to group together diagnosis codes for the purpose of reimbursement and healthcare management. DRGs are used to standardize the way hospitals and other providers are paid for inpatient services. In this system patients are grouped together based on their principal diagnosis in areas referred to as Major Diagnostic Categories (MDC). Once a patient is assigned a particular diagnostic category, providers receive a predetermined payment rate for the services rendered. This reimbursement rate is often fixed and is meant to cover the cost of care for that patient. Reimbursement is also affected by the relative weight of a diagnostic related group based on the severity of a patient's illness and the associated cost of care during hospitalization.

Diagnostic related groups encourage healthcare providers to focus on quality and efficiency in patient care while managing costs effectively. The diagnosis code is present in the following groups for version MS-DRG V41.0 applicable from 10/01/2023 through 09/30/2024.

MS-DRG	MS-DRG Title	MCD	Relative Weight
545	CONNECTIVE TISSUE DISORDERS WITH MCC	08	2.4932
546	CONNECTIVE TISSUE DISORDERS WITH CC	08	1.1993
547	CONNECTIVE TISSUE DISORDERS WITHOUT CC/MCC	08	0.8134

The relative weight of a diagnostic related group determines the reimbursement rate based on the severity of a patient's illness and the associated cost of care during hospitalization.

Convert M33.00 to ICD-9-CM

• ICD-9-CM Code: 710.3 - Dermatomyositis
  Approximate Flag - The approximate mapping means there is not an exact match between the ICD-10 and ICD-9 codes and the mapped code is not a precise representation of the original code.

Patient Education

Myositis

Myositis means inflammation of the muscles that you use to move your body. An injury, infection, or autoimmune disease can cause it. Two specific kinds are polymyositis and dermatomyositis. Polymyositis causes muscle weakness, usually in the muscles closest to the trunk of your body. Dermatomyositis causes muscle weakness, plus a skin rash.

Other symptoms of myositis may include:

• Fatigue after walking or standing
• Tripping or falling
• Trouble swallowing or breathing

Doctors may use a physical exam, lab tests, imaging tests and a muscle biopsy to diagnose myositis. There is no cure for these diseases, but you can treat the symptoms. Polymyositis and dermatomyositis are first treated with high doses of a corticosteroid. Other options include medications, physical therapy, exercise, heat therapy, assistive devices, and rest.

NIH: National Institute of Neurological Disorders and Stroke

[Learn More in MedlinePlus]

Code History

• FY 2024 - No Change, effective from 10/1/2023 through 9/30/2024
• FY 2023 - No Change, effective from 10/1/2022 through 9/30/2023
• FY 2022 - No Change, effective from 10/1/2021 through 9/30/2022
• FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021
• FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
• FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
• FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
• FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
• FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016. This was the first year ICD-10-CM was implemented into the HIPAA code set.